Difference between revisions of "Umbralisib (Ukoniq)"
Jump to navigation
Jump to search
| Line 6: | Line 6: | ||
*[[Marginal zone lymphoma]] | *[[Marginal zone lymphoma]] | ||
| − | == | + | == Manufacturer Package Insert== |
| − | *[https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213176s000lbl.pdf Umbralisib (Ukoniq) | + | *[https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213176s000lbl.pdf Umbralisib (Ukoniq) Package Insert]<ref>[https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213176s000lbl.pdf Umbralisib (Ukoniq) Package Insert]</ref> |
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
Revision as of 22:47, 8 March 2021
Mechanism of action
Phosphatidylinositol 3-kinase (PI3K) isoform p110δ (PI3Kδ) and casein kinase-1ε inhibitor
Diseases for which it is used
Manufacturer Package Insert
History of changes in FDA indication
- 2/5/2021: Approved for adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen.
- 2/5/2021: Approved for adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least three prior lines of systemic therapy.
Also known as
- Code name: TGR-1202
- Brand name: Ukoniq